Strong Pipelines From Allos Therapeutics and Dynavax Tech Poised to Pay Off
13 10월 2011 - 9:16PM
Marketwired
The biotech industry is generating significant investor interest
this year as an influx of new and lucrative therapies work their
way towards regulatory approval. While younger, unprofitable firms
are having difficulty securing funding, reports suggest biotech
companies with promising pipelines should be able to secure
necessary capital. The Bedford Report examines the outlook for
companies in the biotechnology industry and provides equity
research on Allos Therapeutics, Inc. (NASDAQ: ALTH) and Dynavax
Technologies Corporation (NASDAQ: DVAX). Access to the full company
reports can be found at:
www.bedfordreport.com/ALTH
www.bedfordreport.com/DVAX
According to a recent report from Ernst & Young, US biotech
companies raised $25 billion last year -- a 15 percent jump over
the previous year and the highest amount since 2007. Of concern is
that more than 82 percent of that funding went to 20 percent of the
companies. Younger, unprofitable companies in the US that depend on
funding from venture capital firms, stock sales and partnerships
saw available capital decline 21 percent in 2010.
The Bedford Report releases investment research on the
Biotechnology Industry so investors can stay ahead of the crowd and
make the best investment decisions to maximize their returns. Take
a few minutes to register with us free at www.bedfordreport.com and
get exclusive access to our numerous analyst reports and industry
newsletters.
The importance of maintaining a steady pipeline of drugs to
market is having varied effects on the biotechnology industry.
Analysis by the professional services firm BDO argues that larger
pharmaceutical firms are increasing reliance on biotech companies
to fill their pipelines, which has been a net positive for small
biotech companies.
According to Thomson Reuters, on average biotech companies in
the NASDAQ Biotechnology Index (NBI) spent $54 million on R&D
in 2010, reflecting a 7 percent decline from 2009.
The Bedford Report provides Market Research focused on equities
that offer growth opportunities, value, and strong potential
return. We strive to provide the most up-to-date market activities.
We constantly create research reports and newsletters for our
members. The Bedford Report has not been compensated by any of the
above-mentioned publicly traded companies. The Bedford Report is
compensated by other third party organizations for advertising
services. We act as an independent research portal and are aware
that all investment entails inherent risks. Please view the full
disclaimer at http://www.bedfordreport.com/disclaimer.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact: The Bedford Report Email Contact
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (나스닥)의 실시간 뉴스: 최근 기사 0
More The Bedford Report News Articles